Profile: VIVUS Inc (VVUS.OQ)
25 May 2017
VIVUS, Inc., incorporated on May 16, 1996, is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the United States Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended release) for chronic weight management and STENDRA (Avanafil) for erectile dysfunction (ED). The Company is also developing Qsymia for the treatment of Obstructive Sleep Apnea (OSA) and diabetes. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe.
The Company's Qsymia is indicated for chronic weight management as an adjunct to a reduced-calorie diet and physical activity in adult patients with an initial body mass index (BMI) of 30 or greater or obese patients, or a BMI of 27 or greater or overweight patients, in the presence of approximately one weight-related comorbidity, such as hypertension, type II diabetes mellitus or high cholesterol (dyslipidemia). The Company's product incorporates a formulation combining doses of active ingredients from phentermine and topiramate. Qsymia is available in over 40,000 certified retail pharmacies across the country. The Company commercializes Qsymia in the United States through contract sales force, supported by an internal commercial team consisting of sales management, marketing and managed care professionals. The Company has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. The Company also has rights for commercialization of Qsymia for OSA, obesity and diabetes across the world.
The Company's STENDRA is an oral phosphodiesterase type 5 (PDE5) inhibitor. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is an ED medication indicated to be taken approximately 15 minutes before sexual activity. The Company has granted license to Menarini Group to commercialize and promote SPEDRA for the treatment of ED in over 40 European countries, including the Europe, Australia and New Zealand. In addition, it has granted license to Endo International, plc to market STENDRA in the United States and Canada.
The Company competes with Arena Pharmaceutical, Orexigen Therapeutics, Roche, GlaxoSmithKline, Akrimax Pharmaceuticals, LLC, Novo Nordisk A/S, Johnson & Johnson's Janssen Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim and Eli Lilly.
351 E Evelyn Ave
MOUNTAIN VIEW CA 94041-1530
Company Web Links
- BRIEF-Vivus reports Q1 loss per share $0.01
- BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi
- BRIEF-Vivus entered into settlement agreement with Hetero on Jan. 3
- BRIEF-Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH